Analyses of clinical features for responders on imatinib mesylate to Chinese patients with advanced gastrointestinal stromal tumor as first-line treatment: multi-center, eight years followed-up outcome
LIU Xiufeng
LI Jian
LI Yong
ZHOU Yongjian
SHEN Lin
LU Huishan
QIN Shukui
Keywords：Gastrointestinal stromal tumorsImatinib mesylateSurvival advantageSurvival analysis
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：9( 97-105 )